false
0001129928
0001129928
2026-07-06
2026-07-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 6, 2026
Oncolytics
Biotech Inc.
(Exact name of registrant as specified in its charter)
| Nevada |
001-38512 |
98-0541667 |
(State or other
jurisdiction
of incorporation) |
(Commission File Number) |
(IRS Employer
Identification No.) |
|
4350 Executive Drive, Suite 325
San Diego, CA 92121 |
92121 |
| (Address of principal executive offices) |
(Zip Code) |
| |
|
| (403) 670-7377 |
| (Registrant's telephone number, including area code) |
| |
| N/A |
| (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common stock, par value $0.001 per share |
|
ONCY |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 4.01. | Changes in Registrant’s Certifying Accountant. |
On July 6, 2026, due to the
Company’s corporate restructuring, the Audit Committee of the Board of Directors of Oncolytics Biotech Inc. (the “Company”),
unanimously voted to disengage Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting
firm and to engage Baker Tilly US, LLP (“Baker Tilly”) as the Company’s independent registered public accounting
firm for the 2026 fiscal year, subject to completion of Baker Tilly’s client acceptance procedures.
EY’s reports on the
Company’s financial statements for each of the fiscal years ended December 31, 2025 and December 31, 2024 did not contain an adverse
opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles, except
EY’s reports contained an explanatory paragraph regarding the Company’s ability to continue as a going concern. During the
Company’s fiscal years ended December 31, 2025 and December 31, 2024, and through the date of change, there were no disagreements
with EY on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure which, if
not resolved to the satisfaction of EY, would have caused EY to make reference to the subject matter of the disagreement in connection
with its report.
During the fiscal years ended
December 31, 2025 and December 31, 2024 and the subsequent period through the date of change, there have been no reportable events within
the meaning of Item 304(a)(1)(v) of Regulation S-K promulgated by the Securities and Exchange Commission (the “SEC”).
During the fiscal years ended
December 31, 2025 and December 31, 2024 and the subsequent period to the date of its engagement, neither the Company nor anyone acting
on its behalf has consulted with Baker Tilly regarding (i) the application of accounting principles to a specific transaction, either
completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a
written report or oral advice was provided to the Company that Baker Tilly concluded was an important factor considered by the Company
in reaching a decision as to any accounting, auditing, or financial reporting issue; (ii) any matter that was the subject of a disagreement
within the meaning of Item 304(a)(1)(iv) of Regulation S-K; or (iii) any reportable event within the meaning of Item 304(a)(1)(v) of Regulation
S-K.
The Company provided EY with
a copy of this Form 8-K on July 7, 2026, and requested that EY furnish it with a letter addressed to the SEC stating whether it agrees
with the statements made by the Company in this Item 4.01 concerning EY, and, if not, stating the respects in which it does not agree.
The letter of EY addressed to the SEC is attached hereto as Exhibit No. 16.1.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. |
Description |
| |
|
| 16.1 |
Letter from Ernst & Young LLP, dated July 7, 2026. |
| |
|
| 104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
Date: July 8, 2026
| |
ONCOLYTICS BIOTECH INC. |
| |
|
|
| |
By: |
/s/ Kirk Look |
| |
Name: |
Kirk Look |
| |
Title: |
Chief Financial Officer |
